Corbus Pharmaceuticals Holdings, Inc. (CRBP) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-14

Key Insights

Corbus appointed Brent Pfeiffenberger, an experienced pharma executive with significant oncology commercial leadership at Bristol-Myers Squibb and current CEO/Chairman of Century Therapeutics, to its board, expanding it to seven members and signaling potential strategic focus on oncology or commercial expansion.
Stockholders approved a 2024 Equity Compensation Plan amendment increasing authorized shares by 3 million to 5 million total, providing the company with enhanced flexibility for employee equity incentives and potential future acquisitions or strategic transactions.
The board determined Pfeiffenberger meets independence requirements under Nasdaq rules, ensuring proper governance structure, though his initial equity grant terms remain pending board determination and will be disclosed in a future 8-K amendment.

Want the newest filings?

This analysis covers the filing from 2026-05-14. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-05-12

Standard earnings release filing for Q1 2026 fiscal quarter ended March 31, 2026, with the company disclosing financial results and business outlook through a press release.
Information is furnished rather than filed, meaning it is not subject to Section 18 liabilities and will not be automatically incorporated into future SEC filings unless expressly referenced.
CEO Yuval Cohen signed the filing, indicating official company authorization and management's responsibility for the disclosed information and business guidance.

Other reports for Corbus Pharmaceuticals Holdings, Inc.

Quarterly Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.